ID

31668

Description

A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT02225262

Link

https://clinicaltrials.gov/show/NCT02225262

Keywords

Versions (2)
  1. 9/18/18 9/18/18 -
  2. 9/18/18 9/18/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 18, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Prostate Cancer NCT02225262

English

Eligibility Prostate Cancer NCT02225262

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male age ≥ 21
Description

Gender | Age

Data type

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
histologically proven prostate adenocarcinoma
Description

Adenocarcinoma of prostate

Data type

boolean

Alias
UMLS CUI [1]
C0007112
clinical stage t1b-t2b, n0-nx, m0-mx (ajcc 6th edition)
Description

TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1]
C3258246
psa ≤ 20 ng/ml
Description

Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201544
prostate volume ≤ 100 cc
Description

Prostate volume

Data type

boolean

Alias
UMLS CUI [1]
C1441416
patients belonging in one of the following risk groups:
Description

Risk Groups

Data type

boolean

Alias
UMLS CUI [1,1]
C0035647
UMLS CUI [1,2]
C0441833
low:
Description

Low Risk

Data type

boolean

Alias
UMLS CUI [1]
C3538919
cs t1b-t2a and gleason 2-6 and psa ≤ 10
Description

TNM clinical staging | Gleason score | Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1]
C3258246
UMLS CUI [2]
C3203027
UMLS CUI [3]
C0201544
intermediate:
Description

Intermediate Risk

Data type

boolean

Alias
UMLS CUI [1]
C3640764
cs t2b and gleason 2-6 and psa ≤ 10, or
Description

TNM clinical staging | Gleason score | Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1]
C3258246
UMLS CUI [2]
C3203027
UMLS CUI [3]
C0201544
cs t1b-t2b, and gleason 2-6 and psa ≤ 20 ng/ml or gleason 7 and psa ≤ 10 ng/ml
Description

TNM clinical staging | Gleason score | Prostate specific antigen measurement

Data type

boolean

Alias
UMLS CUI [1]
C3258246
UMLS CUI [2]
C3203027
UMLS CUI [3]
C0201544
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any histology other than adenocarcinoma
Description

Histology Any | Exception Adenocarcinoma

Data type

boolean

Alias
UMLS CUI [1,1]
C0344441
UMLS CUI [1,2]
C1552551
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0001418
age < 21
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
kps <= 40 <70
Description

Karnofsky Performance Status

Data type

boolean

Alias
UMLS CUI [1]
C0206065
ecog performance status ≥ 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
patient weight >350 lbs. (table limitation)
Description

Body Weight

Data type

boolean

Alias
UMLS CUI [1]
C0005910
prior xrt to prostate or lower pelvis
Description

Prostate external beam radiation therapy | External Radiation Therapy Pelvis Lower

Data type

boolean

Alias
UMLS CUI [1]
C0860348
UMLS CUI [2,1]
C1517033
UMLS CUI [2,2]
C0030797
UMLS CUI [2,3]
C0441994
prior surgery or cryotherapy to prostate
Description

Operation on prostate | Cryotherapy of prostate

Data type

boolean

Alias
UMLS CUI [1]
C0194790
UMLS CUI [2]
C3544233
implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion
Description

Materials Implanted Preventing Treatment Plan | Materials Implanted Preventing Therapeutic procedure

Data type

boolean

Alias
UMLS CUI [1,1]
C0520510
UMLS CUI [1,2]
C0021102
UMLS CUI [1,3]
C1292733
UMLS CUI [1,4]
C0599880
UMLS CUI [2,1]
C0520510
UMLS CUI [2,2]
C0021102
UMLS CUI [2,3]
C1292733
UMLS CUI [2,4]
C0087111
chemotherapy for a malignancy in the last 5 years
Description

Chemotherapy Malignant Neoplasms

Data type

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0006826
history of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years
Description

Invasive cancer | Exception Prostate carcinoma | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin

Data type

boolean

Alias
UMLS CUI [1]
C0677898
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0600139
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0553723
hormone ablation for 2 months prior to enrollment, or during treatment
Description

Antiandrogen therapy

Data type

boolean

Alias
UMLS CUI [1]
C0279492
Back to the top of the page

Similar models

Eligibility Prostate Cancer NCT02225262

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age
Item
male age ≥ 21
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Adenocarcinoma of prostate
Item
histologically proven prostate adenocarcinoma
boolean
C0007112 (UMLS CUI [1])
TNM clinical staging
Item
clinical stage t1b-t2b, n0-nx, m0-mx (ajcc 6th edition)
boolean
C3258246 (UMLS CUI [1])
Prostate specific antigen measurement
Item
psa ≤ 20 ng/ml
boolean
C0201544 (UMLS CUI [1])
Prostate volume
Item
prostate volume ≤ 100 cc
boolean
C1441416 (UMLS CUI [1])
Risk Groups
Item
patients belonging in one of the following risk groups:
boolean
C0035647 (UMLS CUI [1,1])
C0441833 (UMLS CUI [1,2])
Low Risk
Item
low:
boolean
C3538919 (UMLS CUI [1])
TNM clinical staging | Gleason score | Prostate specific antigen measurement
Item
cs t1b-t2a and gleason 2-6 and psa ≤ 10
boolean
C3258246 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C0201544 (UMLS CUI [3])
Intermediate Risk
Item
intermediate:
boolean
C3640764 (UMLS CUI [1])
TNM clinical staging | Gleason score | Prostate specific antigen measurement
Item
cs t2b and gleason 2-6 and psa ≤ 10, or
boolean
C3258246 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C0201544 (UMLS CUI [3])
TNM clinical staging | Gleason score | Prostate specific antigen measurement
Item
cs t1b-t2b, and gleason 2-6 and psa ≤ 20 ng/ml or gleason 7 and psa ≤ 10 ng/ml
boolean
C3258246 (UMLS CUI [1])
C3203027 (UMLS CUI [2])
C0201544 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Histology Any | Exception Adenocarcinoma
Item
any histology other than adenocarcinoma
boolean
C0344441 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0001418 (UMLS CUI [2,2])
Age
Item
age < 21
boolean
C0001779 (UMLS CUI [1])
Karnofsky Performance Status
Item
kps <= 40 <70
boolean
C0206065 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status ≥ 2
boolean
C1520224 (UMLS CUI [1])
Body Weight
Item
patient weight >350 lbs. (table limitation)
boolean
C0005910 (UMLS CUI [1])
Prostate external beam radiation therapy | External Radiation Therapy Pelvis Lower
Item
prior xrt to prostate or lower pelvis
boolean
C0860348 (UMLS CUI [1])
C1517033 (UMLS CUI [2,1])
C0030797 (UMLS CUI [2,2])
C0441994 (UMLS CUI [2,3])
Operation on prostate | Cryotherapy of prostate
Item
prior surgery or cryotherapy to prostate
boolean
C0194790 (UMLS CUI [1])
C3544233 (UMLS CUI [2])
Materials Implanted Preventing Treatment Plan | Materials Implanted Preventing Therapeutic procedure
Item
implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion
boolean
C0520510 (UMLS CUI [1,1])
C0021102 (UMLS CUI [1,2])
C1292733 (UMLS CUI [1,3])
C0599880 (UMLS CUI [1,4])
C0520510 (UMLS CUI [2,1])
C0021102 (UMLS CUI [2,2])
C1292733 (UMLS CUI [2,3])
C0087111 (UMLS CUI [2,4])
Chemotherapy Malignant Neoplasms
Item
chemotherapy for a malignancy in the last 5 years
boolean
C0392920 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
Invasive cancer | Exception Prostate carcinoma | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin
Item
history of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years
boolean
C0677898 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
Antiandrogen therapy
Item
hormone ablation for 2 months prior to enrollment, or during treatment
boolean
C0279492 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial